DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/krwbh5/seasonal) has announced the addition of the "Seasonal Influenza - Pipeline Review, H2 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Seasonal Influenza, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with the latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Seasonal Influenza and special features on late-stage and discontinued projects.
The report enhances decision-making capabilities and helps to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MoAs to produce first-in-class and best-in-class products.
Companies Mentioned
- AIMM Therapeutics B.V.
- Altimmune, Inc.
- AltraVax Inc.
- AmVac AG
- Big DNA Ltd.
- BioDiem Ltd.
- BiondVax Pharmaceuticals Ltd.
- Celltrion, Inc.
- Cilian AG
- Codagenix, Inc.
- ContraFect Corporation
- Crucell N.V.
- CSL Limited
- Daiichi Sankyo Company, Limited
- Enyo Pharma S.A.S.
- Eurocine Vaccines AB
- FluGen, Inc.
- GlaxoSmithKline Plc
- Hemispherx Biopharma, Inc.
- Imaxio SA
- Johnson & Johnson
- Liquidia Technologies, Inc.
- Medicago Inc.
- Merck & Co., Inc.
- Novavax, Inc.
- OPKO Health, Inc.
- PeptiVir, Inc.
- Protein Sciences Corporation
- TechnoVax, Inc.
- Theraclone Sciences, Inc.
- Touchlight Genetics Limited
- TSRL, Inc.
- Vaxart, Inc.
- Vaxine Pty. Ltd.
- VaxInnate Corporation
For more information visit http://www.researchandmarkets.com/research/krwbh5/seasonal.